Fintel reports that on June 5, 2024, Keybanc initiated coverage of LifeMD (NasdaqGM:LFMD) with a Overweight recommendation.
Analyst Price Forecast Suggests 61.31% Upside
As of June 2, 2024, the average one-year price target for LifeMD is 13.26. The forecasts range from a low of 11.11 to a high of $16.80. The average price target represents an increase of 61.31% from its latest reported closing price of 8.22.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for LifeMD is 213MM, an increase of 30.52%. The projected annual non-GAAP EPS is 0.33.
What is the Fund Sentiment?
There are 120 funds or institutions reporting positions in LifeMD. This is an increase of 13 owner(s) or 12.15% in the last quarter. Average portfolio weight of all funds dedicated to LFMD is 0.10%, an increase of 21.29%. Total shares owned by institutions increased in the last three months by 17.59% to 15,575K shares. 
The put/call ratio of LFMD is 0.20, indicating a bullish outlook.
What are Other Shareholders Doing?
Divisadero Street Capital Management holds 1,693K shares representing 4.00% ownership of the company. In its prior filing, the firm reported owning 1,847K shares , representing a decrease of 9.06%. The firm increased its portfolio allocation in LFMD by 17.80% over the last quarter.
Invesco holds 1,166K shares representing 2.76% ownership of the company. In its prior filing, the firm reported owning 851K shares , representing an increase of 26.97%. The firm decreased its portfolio allocation in LFMD by 85.97% over the last quarter.
DWAS - Invesco DWA SmallCap Momentum ETF holds 939K shares representing 2.22% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Royce & Associates holds 802K shares representing 1.90% ownership of the company. In its prior filing, the firm reported owning 833K shares , representing a decrease of 3.87%. The firm increased its portfolio allocation in LFMD by 15.37% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 693K shares representing 1.64% ownership of the company. In its prior filing, the firm reported owning 568K shares , representing an increase of 18.00%. The firm increased its portfolio allocation in LFMD by 37.86% over the last quarter.
LifeMD Background Information
(This description is provided by the company.)
LifeMD, Inc. (formerly Conversion Labs) is a leading telehealth company that is transforming the healthcare landscape with direct-to-patient product and service offerings. LifeMD's telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient's home.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
